- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Michael Reff on Medically Integrated Dispensary in Value-Based Care
Michael Reff, executive director of National Community Oncology Dispensing Association (NCODA), discusses the role of the medically integrated dispensary in the transition to value-based payment models.
Michael Reff, executive director of National Community Oncology Dispensing Association (NCODA), discusses the role of the medically integrated dispensary in the transition to value-based payment models.
Transcript
Where do you see the role of the oncology pharmacist in value-based care?
I think the pharmacist or the medically integrated dispensary plays a tremendous role in those value-based pathways. In a sense that the medically integrated personnel need to ensure that there’s that continuity of care that we all talk about and to take additional cost of waste out of the system to ensure that the patient’s getting the right drug at the right time.
NCODA has developed a tool to help out practices capture cost avoidance and also waste that’s associated with prescriptions filled through specialty pharmacy. But more importantly, the cost avoidance tool captures the value in the amount of dispenses that are not completed in order to take cost away from the health system that would have been normally dispensed in a specialty pharmacy platform.
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
